| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Selexipag (JAN/USAN/INN); Uptravi (TN) | ||||||||
| Product | SELEXIPAG (Actelion Pharmaceuticals US) | ||||||||
| Formula | C26H32N4O4S | ||||||||
| Exact mass | 496.2144 | ||||||||
| Mol weight | 496.6217 | ||||||||
| Structure |  | ||||||||
| Class | Blood modifier agent DG01950 Antithrombotic agent DG01712 Antiplatelet agent Metabolizing enzyme substrate DG02918 CYP2C8 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG02924 UGT substrate DG03184 UGT1A3 substrate DG03190 UGT2B7 substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Antihypertensive, Vasodilator, Prostaglandin I2 receptor agonist | ||||||||
| Disease | Pulmonary arterial hypertension [DS:H01621] | ||||||||
| Target | PTGIR [HSA:5739] [KO:K04263] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Enzyme: CYP2C8 [HSA:1558], CYP3A4 [HSA:1576], UGT1A3 [HSA:54659], UGT2B7 [HSA:7364] | ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] B BLOOD AND BLOOD FORMING ORGANS B01 ANTITHROMBOTIC AGENTS B01A ANTITHROMBOTIC AGENTS B01AC Platelet aggregation inhibitors excl. heparin B01AC27 Selexipag D09994 Selexipag (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Respiratory Tract/Pulmonary Agents Pulmonary Antihypertensives Prostacyclin Receptor Agonist Selexipag D09994 Selexipag (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 21 Cardiovascular agents 219 Miscellaneous 2190 Miscellaneous D09994 Selexipag (JAN/USAN/INN) Drug groups [BR:br08330] Blood modifier agent DG01950 Antithrombotic agent DG01712 Antiplatelet agent D09994 Selexipag Metabolizing enzyme substrate DG02918 CYP2C8 substrate D09994 Selexipag DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D09994 Selexipag DG02924 UGT substrate DG03184 UGT1A3 substrate D09994 Selexipag DG03190 UGT2B7 substrate D09994 Selexipag Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Prostacyclin PTGIR D09994 Selexipag (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D09994 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D09994 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D09994 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D09994 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D09994 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 35 1 C8y C 11.7600 -18.3400 2 C8y C 11.7600 -19.7400 3 N5x N 12.9724 -20.4400 4 C8x C 14.1849 -19.7400 5 C8y C 14.1849 -18.3400 6 N5x N 12.9724 -17.6400 7 C8y C 10.5476 -17.6400 8 C8y C 10.5476 -20.4400 9 C8x C 10.5476 -16.2402 10 C8x C 9.3351 -15.5402 11 C8x C 8.1227 -16.2402 12 C8x C 8.1227 -17.6400 13 C8x C 9.3351 -18.3400 14 C8x C 9.3521 -19.7496 15 C8x C 8.1396 -20.4495 16 C8x C 8.1394 -21.8495 17 C8x C 9.3349 -22.5399 18 C8x C 10.5474 -21.8400 19 N1c N 15.4160 -17.6290 20 C1b C 16.6212 -18.3247 21 C1c C 15.4157 -16.2401 22 C1a C 14.1914 -15.5334 23 C1a C 16.6162 -15.5466 24 C1b C 17.8035 -17.6419 25 C1b C 18.9975 -18.3312 26 C1b C 20.1854 -17.6452 27 O2a O 21.3765 -18.3329 28 C1b C 22.5659 -17.6461 29 C5a C 23.7562 -18.3334 30 N1b N 24.9461 -17.6463 31 S4a S 26.1362 -18.3335 32 O5a O 23.7564 -19.7398 33 C1a C 27.3486 -19.0335 34 O3c O 25.4271 -19.5621 35 O3c O 26.8265 -17.1373 BOND 37 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 1 7 1 8 2 8 1 9 7 9 2 10 9 10 1 11 10 11 2 12 11 12 1 13 12 13 2 14 7 13 1 15 8 14 2 16 14 15 1 17 15 16 2 18 16 17 1 19 17 18 2 20 8 18 1 21 5 19 1 22 19 20 1 23 19 21 1 24 21 22 1 25 21 23 1 26 20 24 1 27 24 25 1 28 25 26 1 29 26 27 1 30 27 28 1 31 28 29 1 32 29 30 1 33 30 31 1 34 29 32 2 35 31 33 1 36 31 34 2 37 31 35 2 |